Iovance Biotherapeutics Inc. [NASDAQ: IOVA] closed the trading session at $51.06 on 01/15/21. The day’s price range saw the stock hit a low of $50.46, while the highest price level was $54.2081. The company report on December 28, 2020 that Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Maria Fardis, PhD, MBA, President and Chief Executive Officer of Iovance, plans to present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021, at 10:50 a.m. ET. The live and archived webcasts of the presentation and breakout session will be available in the Investors section of the Iovance website at http://ir.iovance.com.
About Iovance Biotherapeutics, Inc.Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment. For more information, please visit www.iovance.com.
The stocks have a year to date performance of 10.04 percent and weekly performance of 1.07 percent. The stock has been moved at 66.81 percent over the last six months. The stock has performed 6.78 percent around the most recent 30 days and changed 41.64 percent over the most recent 3-months.
If compared to the average trading volume of 1.24M shares, IOVA reached to a volume of 981237 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Iovance Biotherapeutics Inc. [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $51.45 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Iovance Biotherapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 15, 2020. The new note on the price target was released on October 06, 2020, representing the official price target for Iovance Biotherapeutics Inc. stock. Previously, the target price had yet another raise to $61, while Mizuho analysts kept a Buy rating on IOVA stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc. is set at 3.07 The Price to Book ratio for the last quarter was 10.51, with the Price to Cash per share for the same quarter was set at 4.78.
IOVA stock trade performance evaluation
Iovance Biotherapeutics Inc. [IOVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.07. With this latest performance, IOVA shares gained by 6.78% in over the last four-week period, additionally plugging by 66.81% over the last 6 months – not to mention a rise of 115.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 61.14, with the RSI for the last a single of trading hit 60.84, and the three-weeks RSI is set at 61.45 for Iovance Biotherapeutics Inc. [IOVA]. The present Moving Average for the last 50 days of trading for this stock 44.15, while it was recorded at 50.90 for the last single week of trading, and 35.19 for the last 200 days.
Iovance Biotherapeutics Inc. [IOVA]: An insightful look at the core fundamentals
Iovance Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.20 and a Current Ratio set at 11.20.
Earnings per share (EPS) analysis for Iovance Biotherapeutics Inc. [IOVA] stock
With the latest financial reports released by the company, Iovance Biotherapeutics Inc. posted -0.5/share EPS, while the average EPS was predicted by analysts to be reported at -0.41/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IOVA.
Iovance Biotherapeutics Inc. [IOVA]: Insider Ownership positions
There are presently around $7,063 million, or 99.22% of IOVA stock, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 11,778,527, which is approximately -3.679% of the company’s market cap and around 0.77% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 10,085,632 shares of the stock with an approximate value of $514.97 million in IOVA stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $486.91 million in IOVA stock with ownership of nearly -7.963% of the company’s market capitalization.
125 institutional holders increased their position in Iovance Biotherapeutics Inc. [NASDAQ:IOVA] by around 12,410,977 shares. Additionally, 142 investors decreased positions by around 13,442,780 shares, while 28 investors held positions by with 112,479,477 shares. The mentioned changes placed institutional holdings at 138,333,234 shares, according to the latest SEC report filing. IOVA stock had 45 new institutional investments in for a total of 2,891,214 shares, while 49 institutional investors sold positions of 1,642,461 shares during the same period.